|Articles|May 13, 2010
IntraLinks Announces Partnership with SAFE-BioPharma; Will Provide Digital Identity Capabilities with its Life Sciences Solutions
Advertisement
IntraLinks
, a provider of critical information exchange solutions,
announced a partnership
with
SAFE-BioPharma
, the non-profit association that created and manages the SAFE-BioPharma® digital identity and signature standard for the pharmaceutical and healthcare industries. IntraLinks users will now be able to use the SAFE-BioPharma digital identity for signing documents. They can increase clinical trial efficiency by signing paperwork with a SAFE credential that provides additional security and speed, eliminating printing of hard copy casebooks and other documents.
Users will have the opportunity to upload and use their SAFE-BioPharma digital identities on the IntraLinks® platform, ensuring that their credentials are available anywhere via the Web. IntraLinks is also enabling documents signed with SAFE-BioPharma signatures to be stored and shared on its existing platform.
“Incorporating SAFE-BioPharma’s digital identity and signature standard into IntraLinks’ platform is very significant for our clients and the community who rely on IntraLinks to manage their clinical trial communication and document exchange,” said Alison Shurell, VP, life sciences product marketing, IntraLinks. “In addition to already being able to securely upload, receive, review and distribute documents on IntraLinks, sponsors, CROs and investigators will soon be able to eliminate the need to print out or physically store the numerous documents that require signatures during a clinical trial."
In addition to incorporating the digital signature into its platform, IntraLinks has joined the SAFE-BioPharma vendor partner community.
Users will have the opportunity to upload and use their SAFE-BioPharma digital identities on the IntraLinks® platform, ensuring that their credentials are available anywhere via the Web. IntraLinks is also enabling documents signed with SAFE-BioPharma signatures to be stored and shared on its existing platform.
“Incorporating SAFE-BioPharma’s digital identity and signature standard into IntraLinks’ platform is very significant for our clients and the community who rely on IntraLinks to manage their clinical trial communication and document exchange,” said Alison Shurell, VP, life sciences product marketing, IntraLinks. “In addition to already being able to securely upload, receive, review and distribute documents on IntraLinks, sponsors, CROs and investigators will soon be able to eliminate the need to print out or physically store the numerous documents that require signatures during a clinical trial."
In addition to incorporating the digital signature into its platform, IntraLinks has joined the SAFE-BioPharma vendor partner community.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Articles
- Q&A: Strategies for Successful Global Clinical Trial Delivery
September 12th 2025
- Vabysmo Shows Long-Term Efficacy and Safety in Wet AMD, PCV Patients
September 12th 2025
- Latest NIMBLE Study Results Highlight Progress in gMG Research
September 12th 2025
- ACT Brief Episode 8: Expert Insights on the Future of Obesity Drug Trials
September 11th 2025
Advertisement
Advertisement